Versameb AG, a Basel, Switzerland-based biopharmaceutical company, closed a CHF 6.4m a Seed C financing round.
The round brought the total capital raised to date to CHF 11.8m.
The company intends to use the funds to expand its proprietary technology platform, VERSagile, in multiple indications and advance the lead program towards clinical studies.
Led by Prof. Dr. Friedrich Metzger, CEO, Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs. The VERSagile technology platform enables efficient development of functional mRNA molecules for customized protein expression and modification in various therapeutic indications.
At the 2019 Annual Shareholder Meeting, Dr. Reinhard Ambros was elected as a Member of the Board of Directors and was subsequently appointed Chairman succeeding Roger Meier.
In addition, Versameb has recently appointed Dr. Isabel Ferreira as Chief Business Officer. In her role, Ferreira will be responsible for leading the company’s global partnering and corporate development strategy and execution.
Isabel Ferreira served most recently in Roche Partnering as Director Global Business Development, led strategic projects and cross-functional teams to deal closure.
Prior to joining Roche, she acted as Senior Director Business Development in a Dutch Biotech company that was listed on NASDAQ in a successful IPO in 2013 and was acquired by BioMarin early 2015.